Kornimate/medical-research-clean huggingface dataset:
comparative study between early vitrectomy and observation for spontaneous closure of traumatic macular hole

Conditions: Trauma; Macular Hole

Summary: the purpose of this study is to compare the anatomical and visual recovery of eyes with traumatic macular hole (tmh) following either early vitrectomy or 6-month observation.

patients who received vitrectomy immediately after the injury were compared with patients who were observed for six months for spontaneously closure.the closure rate, foveal microstructure, and final visual acuity were analyzed.

Eligibility criteria:
inclusion criteria: * closed globe injury * identification of full-thickness macular hole by optical coherence tomography within one month after trauma exclusion criteria: * open globe injury * coexistence of idiopathic macular hole * severe opaque in the visual axis caused by the injury(eg. severe cataract, severe vitreous hemorrhage) * combined injuries requiring immediate surgical intervention (eg. lens dislocation, retinal detachment, cyclodialysis) * coexistence of high myopia * coexistence of choroidal rupture or subretinal hemorrhage within the diameter of 400μm from the center of the foveola * coexistence of severe optic nerve injury (no light perception, positive afferent pupillary defect)

Keywords: traumatic macular hole vitrectomy observation
study utilizing biozek covid-19 antigen rapid test.

Conditions: Covid19

Summary: this is a research study to evaluate the sensitivity and specificity of biozek covid-19 antigen rapid test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results. in addition, to obtain rt-pcr test results, performed prior to enrollment, and compare all three results.


Eligibility criteria:
inclusion criteria: subjects must be ≥18 years of age and have had an rt-pcr test performed prior to enrollment. subjects must be able to understand and willingly sign a written informed consent. additionally, participants need to meet at least 1 of the criteria listed below: * currently experiencing symptoms of covid-19. * be clinically diagnosed or suspected to have covid-19. * recent past (3 weeks) exhibited symptoms of covid-19. * be capable of performing a self-collection of a nasopharyngeal sample with use of nasal swab kit. * interacted with a covid-19 positive individual. exclusion criteria: subjects who meet any of the following exclusion criteria may not be enrolled in this study: * cannot perform self-collection of a nasopharyngeal sample with use of nasal swab kit. * have a deviated nasal septum. * cognitively impaired individuals resulting in the inability to provide informed consent
restless legs patient study on absorption, distribution, metabolism and excretion of ropinirole and the effect of food

Conditions: Restless Legs Syndrome

Summary: this study in rls patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat breakfast), and to assess the difference in absorption, distribution, metabolism and excretion of ropinirole if patients are given two 3mg ropinirole tablets versus one 6mg tablet.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of rls * body mass index of 18 to 32 kg/m², with a body weight of at least 50 kg * normal blood pressure pre-study * light smokers only (\<20/day) exclusion criteria: * history of postural hypotension or faints * secondary rls * patients who suffer from a primary sleep disorder other than rls * patients diagnosed with movement disorders * patients with unstable medical conditions * patients with personal or family history of adverse reactions or hypersensitivity to the study drug * patients with abnormal laboratory values * patients with hepatitis or hiv * patients who abuse alcohol or drugs * patients taking the following medications: dopamine agonists (including ropinirole), dopamine antagonists (e.g., metoclopramide and domperidone), levodopa/carbidopa

Keywords: pharmacokinetic, rls formulation, food effect, controlled release for rls, sk&f101468,
compare the effect of ins alone and added ltra in treatment of sar

Conditions: Allergic Rhinitis

Summary: it is not proven unequivocally whether a combination of an intranasal corticosteroids (ins) and a cysteinyl leukotriene receptor antagonist has greater efficacy than ins in the treatment of severe allergic rhinitis (ar) . we performed a randomized, open-label study in 46 seasonal ar subjects receiving budesonide (bd, 256ug) plus montelukast (mnt, 10 mg) or bd alone (256ug) for 2 weeks. visual analog scale (vas) scores, nasal cavity volume (ncv), nasal airway resistance (nar) and fractional exhaled nitric oxide (feno) were assessed before and at end of treatments as the primary treatment outcomes. similarly, histamine, eosinophil cationic protein (ecp) and cysteinyl-leukotrienes (cyslts) in nasal secretion and th1/th2 cells in nasal mucosa were evaluated as the secondary treatment outcomes.


Eligibility criteria:
inclusion criteria: * moderate to severe seasonal allergic rhinitis * confirmed to had a diagnosis of sar and also shown to be sensitized to mugwort allergen * had not received any therapies for ar or antibiotics for at least 7 days before their outpatient clinic visit prior to the study exclusion criteria: * smokers * asthma (based on patient's history and pulmonary function tests) * had any other chronic disease * pregnant women

Keywords: budesonide montelukast combination therapy monotherapy
voltage-based contrast media adaptation in coronary computed tomography angiography

Conditions: Coronary Artery Disease; Cardiovascular Diseases

Summary: the purpose of this study is to prospectively evaluate the effectiveness of low-volume contrast media (cm) injection protocols adapted to tube voltage in patients undergoing coronary computed tomography angiography (ccta).


Eligibility criteria:
inclusion criteria: 1. referred for a clinically indicated ccta scan. 2. subject must be 18 - 85 years of age. 3. subject must provide written informed consent prior to any study-related procedures being performed. 4. subject must be willing to comply with all clinical study procedures. exclusion criteria: 1. subject is a pregnant or nursing female. exclude the possibility of pregnancy: * by testing (serum or urine beta hcg) within 24 hours before study agent administration, or * by surgical sterilization, or * post-menopausal, with minimum one (1) year history without menses. 2. subject is chosen by the automated tube voltage selection algorithm (or adjusted by the technologist) to be scanned using a tube voltage that is not 70, 80, 90, 100, 110, 120, or 130 kv. 3. subject is chosen by the automated tube voltage selection algorithm (or adjusted by the technologist) to be scanned using a tube voltage that has previously reached the maximum subject number (20 subjects per tube voltage). 4. subject has an acute psychiatric disorder. 5. subject is unwilling to comply with the requirements of the protocol. 6. subject has previously entered this study. 7. subject has an allergy against iodinated contrast agents or pharmaceutical stressors used in this study. 8. subject has impaired renal function (creatinine \> 1.5 mg/dl). 9. subject is in unstable condition.

Keywords: computed tomography
aneufix - prophylactic sac filling

Conditions: Abdominal Aortic Aneurysm; Endoleak

Summary: this study is set up to assess the feasibility and safety of the clinical procedure using aneufix in a prophylactic setting at the time of evar endograft implantation.

the investigational device is called aneufix, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries. aneufix is a polymer that cures rapidly (2-4 min at 37°c) after injection into the aaa-sac close to the nidus.

Eligibility criteria:
inclusion criteria: * asymptomatic, infrarenal aaa that requires surgery with a high-risk profile of developing endoleak type ii in line with the recommendations of guntner et al: - open ima and * 1 patent lumbar and a cross-sectional area at the location of the ima (csaima) \>17,5cm2 or * 2 patent lumbars and a csaima \>15cm2 or * 3 patent lumbars and a csaima \>12,5 cm2 or * 4 patent lumbars and a csaima \>10 cm2 or * 5 patent lumbars and a csaima \>7,5 cm2 * infrarenal neck according to the ifu of the evar device * other aortic-iliac anatomical configuration suitable for evar according to the criteria of the evar device to be used * patient having a life expectation of at least 2 years * being older than 18 years * willing and able to comply with the requirements of this clinical study exclusion criteria: * patient not able or willing to give written informed consent * patient undergoing emergency procedures * patient undergoing evar for ruptured or symptomatic aaa, * patient with a suprarenal aaa * patient with an inflammatory aaa (more than minimal wall thickening) * patient with an infrarenal neck unsuitable for endovascular fixation (including so called "hostile necks") or aortic-iliac anatomic configuration otherwise unsuitable for evar according to criteria of the device to be used * patient in which a bilateral retroperitoneal incision is required for evar * patient in which a sacrifice of both hypogastric arteries is required * patient with anatomical variations, i.e. horseshoe-kidney, arteries requiring reimplantation * patient in which the administration of contrast agent is not possible: proved, severe systemic reaction to contrast agent * patient with active infection present * patients scheduled for or having received an organ transplant * patient with limited life expectation due to other illness (\<1 year) * patient with non-iatrogenic bleeding diathesis * patient with connective tissue disease * women of child-bearing potential * patients with evidence at completion angiogram during evar of a type ia or type iii endoleak persistent after balloon inflation
non-invasive monitoring of miscarriage

Conditions: Miscarriage in First Trimester

Summary: cfdna is extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. this study aims to determine the level of cell-free dna (cfdna) in early pregnancy and compare the results with those of product of conception (poc) testing, in concordance with standard karyotyping.

pregnancies achieved by assisted reproductive technologies (art) are closely monitored, therefore miscarriages that occur very early in the pregnancy are frequently meticulously recorded and reported. on the other hand, spontaneous abortion rates among naturally occurring conceptions are notoriously hard to quantify and are often overstated when using criteria from assisted reproductive technologies. additionally, women who have undergone treatment with art are a particular population with traits that can make them more vulnerable to spontaneous abortions. cfdna would be extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. this study aims to determine the level of cell-free dna (cfdna) in early pregnancy and compare the results with those of product of conception (poc) testing, in concordance with standard karyotyping.

Eligibility criteria:
inclusion criteria: 1. age 18-45 years. 2. women who attend the early pregnancy loss clinic or patients who receive art 3. their partner, the biological father of the pregnancy exclusion criteria: * history of psychological/ psychiatric problem * patient refusal
the effect of high intensity laser on muscle quality and pain in those with low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate the effects of curewave laser on paraspinal muscle oxygenation, pressure pain thresholds, muscle edema, and quality, and perceived outcomes in patients with chronic low back pain.

low back pain (lbp) contributes to disability and has a significant economic impact. high intensity laser devices are class 4 producing \> 40 w of power at longer wavelengths, thereby allowing deeper tissue penetration. currently, there is little evidence to demonstrate the effectiveness of high intensity laser treatment in those with chronic lbp. optimal dosing strategies are still unknown as well as patient response based on chronicity of symptoms. therefore, our study seeks to evaluate the effectives of high intensity laser therapy using curewave in those with lbp of a duration longer than 3 months and with a dosing strategy of two times/week for three weeks. hypothesis 1. curewave laser therapy will increase total oxygenated hemoglobin and muscle blood flow in patients with chronic lbp. 2. curewave laser therapy will reduce inflammation as assessed by muscle edema in patients with chronic lbp. 3. curewave laser therapy will improve paraspinal echogenicity (muscle quality) following treatment in patients with chronic lbp. 4. curewave laser therapy will decrease muscle sensitivity in patients with chronic lbp 5. curewave laser therapy will demonstrate improve patient reported outcomes, including decreased pain, reduced disability and improved function in patients with chronic lbp. 6. curewave laser therapy will increase muscle activation during maximal strength testing. 7. curewave laser therapy will decrease performance fatigability as assessed by maximal muscle activation and force production.

Eligibility criteria:
inclusion criteria: * age 18-65 * self-reported history of low back pain (5 episodes in lifetime or 3 in last three years which altered activities of daily living)13 exclusion criteria: * self-reported pregnancy * inability to complete all required meeting sessions * known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease * regularly uses prescription medication * seeking medical care for the current episode of low back pain * report average symptoms greater than 8/10 * inability to perceive light touch. * verbal reports of known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease * verbal reports of known skin sensitivity to gels or adhesives.

Keywords: low back pain laser perceived pain perceived disability
posterior nasal nerve combined with anterior ethmoid neurotomy for idiopathic rhinitis

Conditions: Idiopathic Rhinitis

Summary: the present study was a randomised, parallel controlled, open-label, multicentre clinical study. the trial was divided into two groups, the posterior nasal nerve combined with anterior ethmoid neurotomy group (group a) and the conventional drug treatment group (group b). patients with idiopathic rhinitis (ir) who met the inclusion criteria were included in a 7-day introductory period of nasal spray hormone (budesonide nasal spray) treatment. subjects with ir who met the randomization criteria after the introductory period were randomized 1:1 to either group a or group b for a 1-year treatment follow-up study. in group a, subjects will undergo the posterior nasal nerve combined with anterior ethmoid neurotomy. in group b, subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. oral antihistamines (loratadine) or nasal antihistamines (azelastine hydrochloride) are preferred, and nasal hormones (budesonide nasal spray), or a combination of two or three drugs, may be used in severe cases. participants will be evaluated for safety and efficacy throughout the entire three-year period.


Eligibility criteria:
inclusion criteria: 1. patients signed the free and informed consent form and understood the explanation of the study. 2. patients with ir between 18 and 65 years and their body mass index (bmi) should be ≥19 kg/m2 and ≤24 kg/m2. 3. patients diagnosed with idiopathic rhinitis （ir）that were defined as nonsmoking patients with at least 2 nasal complaints of nasal obstruction, rhinorrhea, itching, and/or sneezing for more than 1 hour a day and for more than 1 year. 4. patients with negative skin prick test (spt) responses or sige 5. nasal cytological exam with eosinophilia less than 20%. 6. patients had a total nasal symptom score (tnss) of ≥6 and a subscore of nasal discharge ≥2 and a subscore of nasal congestion ≥1. exclusion criteria: 1. patients with colored secretions, inflammation，nasal polyps, chronic sinusitis, nasal tumours. 2. patients with other chronic rhinitis such as occupational rhinitis, drug rhinitis, gustatory rhinitis, hormonal rhinitis, atrophic rhinitis, etc. 3. patients with anatomic nasal abnormalities responsible for nasal symptoms. 4. patients with nasal/sinus surgery 3 months before the study. 5. patients with severe mental illness. 6. patients with uncontrolled asthma, systemic disorders or malignancies. 7. patients with history of chronic smoking, substance abuse, drug use, and/or excessive alcohol consumption. 8. patients in pregnancy or lactation.

Keywords: idiopathic rhinitis posterior nasal nerve neurotomy anterior ethmoid neurotomy surgical treatment neuroimmune
pseudo-pdt in central serous chorioretinopathy

Conditions: Chronic Central Serous Chorioretinopathy

Summary: acute central serous chorioretinopathy (csc) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. we evaluated half-dose verteporfin photodynamic therapy (hd-pdt) versus 689 nm laser treatment in chronic csc. twenty-two eyes of 22 patients with symptomatic chronic csc were randomized in a 1:1 ratio to receive hd-pdt (group 1) or 689-lt delivering 95 j/cm2 by application of an intensity of 805 mw/cm2 over 118 seconds. best-corrected visual acuity (bcva) and spectral-domain optical coherence tomography findings were compared between groups.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * patients with best-corrected visual acuity (bcva) of 20/200 or better; * presence of subretinal fluid (srf) and/or serous pigment epithelial detachment involving the fovea on optical coherence tomography (oct); * presence of active angiographic leakage in fluorescein angiography caused by csc and no other diseases, and abnormal dilated choroidal vasculature and other features in indocyanine green angiography (icga) consistent with the diagnosis of csc. exclusion criteria: * any previous treatment for csc; * evidence of choroidal neovascularization or other maculopathy on fundus examination.
photoacoustic endoscopy of barrett's esophagus

Conditions: Barrett Esophagus

Summary: endoscopy is an important technique in medicine to diagnose internal organs. video endoscopy has been the most common technique providing clear, real time video images of organs' surfaces. however, this technique only images the surface and cannot effectively diagnose diseased tissues that develop in endothelial tissues. endoscopic ultrasound (eus) has been developed to overcome this limitation, and it is widely utilized in diagnosing gi diseases. this technique can image very deep areas of organs, up to several centimeters; however, it suffers from speckle artifacts and cannot adequately provide early diagnosis of tissue abnormalities that do not show mechanical properties that differ significantly from those of normal tissues. the investigators propose that photoacoustic endoscopy (pae), an endoscopic embodiment of the rapidly growing photoacoustic tomography (pat) technology, can fulfill the aforementioned need.


Eligibility criteria:
inclusion criteria: * aged 18 years and older. * patients with barrett's esophagus scheduled for esophageal surgery. * patients with gerd, but without barrett's esophagus, scheduled for esophageal surgery. * subjects must be able to understand and willing to sign a written informed consent form. exclusion criteria: * inability to give informed consent. * pregnancy. * age less than 18 years * previous esophageal procedure (surgery, photodynamic therapy, argon plasma coagulation, endoscopic mucosal resection). * acute gi bleeding. * coagulopathy.
falls prevention in osteoporosis

Conditions: Osteoporosis

Summary: the purpose of this study is to determine wether a falls prevention program can reduce fall incidence in people with osteoporosis.

falling is a major health problem in the elderly causing physical and psychosocial problems. people with osteoporosis are at higher risk for fractures due to falling, because of decreased bone strength. the 'nijmegen falls prevention program" (nfpp) (weerdesteyn et al, 2006) has been shown to reduce fall incidence rates by 46% in healthy community-dwelling elderly. this program was adapted in order to meet the specific demands and constraints of people with osteoporosis. the contents of the program are an obstacle course, walking exercises, the practice of fall techniques, adjustment of gait abnormalities, weight bearing exercises and educational sessions. the effectiveness of the program will be evaluated in a randomized clinical trial. primary outcome measure is fall incidence. additionally, laboratory assessments of gait and obstacle avoidance will be conducted in conjunction with questionnaires about balance confidence and activity level.

Eligibility criteria:
inclusion criteria: * osteoporosis (dxa t-score \< -2.5 in hip and/or vertebrae) * able to walk at least 15 minutes without an helping device * 65 years or older * community dwelling * at least one fall in the prior year exclusion criteria: * severe cardiac, pulmonary or musculoskeletal disorders * pathologies associated with increased fall risks (i.e. stroke or parkinson's disease) * use of psychotropic drugs

Keywords: osteoporosis falls prevention elderly exercise incidence obstacle avoidance
antenatal relaxation group for anxiety and depression management

Conditions: Anxiety; Depression

Summary: approximately 20% of pregnant women experience depression. untreated depression during pregnancy is linked to decreased prenatal care, difficulties in the pregnancy, poorer outcomes for the baby, and developmental, language, and behaviour problems in the older child. while medication can often offer relief, pregnant women suffering with depression are often reluctant to take medications that may affect the unborn baby. there is little research about the effectiveness of other treatments such as support groups. the investigators project will provide relaxation groups for pregnant women with anxiety and depression. the group will provide a chance to get support from other pregnant women. two health care specialists will provide information about anxiety and depression. they will also teach the skills for women to manage their symptoms. women will be asked to complete a few questionnaires to evaluate their symptoms before, during, and after they join the group. they will also be asked to evaluate how the group met their needs.

pregnant women between 15-28 weeks, who speak english are invited to join an 8 week group to relieve anxiety and depression. we have collected sociodemographic data, as well as social support, life events. outcome measures are a decrease in anxiety and depression-as measured by the edinburgh postnatal depression scale, the cambridge worry scale, and the stai-trait scale.

Eligibility criteria:
inclusion criteria: * 15 to 28 weeks pregnant and english speaking exclusion criteria: * non-english speaking

Keywords: anxiety depression pregnancy antenatal prenatal mindfulness-based therapy interpersonal therapy support groups